Overview

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This trial was performed in patients with idiopathic pulmonary fibrosis (IPF) to evaluate the clinical efficacy and safety of different doses of TDI01 Suspension, compared with control, for the treatment of patients with IPF.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Tide Pharmaceutical Co., Ltd